Drug therapy of pemphigus vulgaris

Giornale Italiano di Dermatologia e Venereologia

Volumn 142, Issue 4, 2007, Pages 391-408

  Ahmed, A R ^a  

^a NEW ENGLAND BAPTIST HOSPITAL   (United States)

Author keywords

Immunotherapy; Pemphigus, diagnosis; Pemphigus, drug therapy

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CD20 ANTIBODY; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; ETANERCEPT; FOLIC ACID; GOLD; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEMPHIGUS ANTIBODY; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VINCRISTINE;

ADJUVANT THERAPY; ALOPECIA; AMENORRHEA; B LYMPHOCYTE; BLADDER CANCER; BLISTER; BRONCHOSPASM; CELL SURFACE; CHILL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEVER; FOLLOW UP; GRAM NEGATIVE SEPSIS; HEART DISEASE; HEMATOLOGIC DISEASE; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INFERTILITY; KERATINOCYTE; LEUKOPENIA; LUNG ABSCESS; LUNG TUBERCULOSIS; MONOTHERAPY; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAUSEA; OBESITY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PATHOGENESIS; PEMPHIGUS VULGARIS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PLASMAPHERESIS; PNEUMONIA; PRURITUS; QUALITY OF LIFE; RECURRENT DISEASE; REMISSION; REVIEW; SEPTICEMIA; SKIN MANIFESTATION; STEM CELL; SYMPTOM; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION;

EID: 36049012779     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (159)

1. Yeh SW, Sami N, Ahmed AR. Treatment of pemphigus vulgaris. Am J Clin Dermatol 2005;6:327-42.
2. Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations and management. Crit Rev Oral Biol Med 2002;13:397-408.
3. Lever WF, White H. Treatment of pemphigus with corticosteroids: results obtained in 46 patients over a period of 11 years. Arch Dermatol 1963;87:12-26.
4. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus: an update. Arch Dermatol 1996;132:203-12.
5. Truhan AP, Ahmed AR. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989;62:375-91.
6. Lever WF. Pemphigus vulgaris. Arch Dermatol 1970;102:114-6.
7. Fellner MJ, Sapadin AN. Current therapy of pemphigus vulgaris. Mt Sinai J Med 2001;68:268-78.
8. Haim S, Friedman-Birnbaum R. Dapsone in the treatment of pemphigus vulgaris. Dermatologica 1978;156:120-3.
9. Chiang H, Sirois DA, Bielory L. Chronic oral mucosal ulceration in a 54-year-old female. Ann Allergy Asthma Immunol 2000;84:391-5.
10. Piamphongsant T. Pemphigus controlled by dapsone. Br J Dermatol 1976;94:681-6.
11. Pearson RW, O'Donoghue M, Kaplan SJ. Pemphigus vegetans: its relationship to eosinophilic spongiosis and favorable response to dapsone. Arch Dermatol 1980;116:65-8.
12. Ahmed AR, Salm M. Juvenile pemphigus. J Am Acad Dermatol 1983;8:799-807.
13. Rodan KP, Hu CH, Nickoloff BJ. Malodorous intertriginous pustules and plaques: pemphigus vegetans, Hallopeau type. Arch Dermatol 1987;123:393, 396-7.
14. Barnard GP, Scharf MJ, Dagher RK. Sulfone syndrome in a patient receiving steroids for pemphigus. Am J Gastroenterol 1994;89:2057-9.
15. Bjarnason B, Skoglund C, Flosadottir R. Childhood pemphigus vulgaris treated with dapsone: a case report. Pediatr Dermatol 1998;15:381-3.
16. Tan HH, Tay YK. An unusual case of pemphigus vulgaris presenting as bilateral foot ulcers. Clin Exp Dermatol 2000;25:224-6.
17. Rogers RS, Sheridan PJ, Nightingale SH. Desquamative gingivitis: clinical, histopathologic, immunopathologic, and therapeutic observations. J Am Acad Dermatol 1982;7:729-35.
18. Peck SM, Osserman KE. Studies in bullous diseases: treatment of pemphigus vulgaris with methotrexate, two patients (one with concurrent myasthenia gravis). J Mt Sinai Hosp NY 1969;36:71-6.
19. Lever WF, Goldberg HS. Treatment of pemphigus vulgaris with methotrexate. Arch Dermatol 1969;100:70-8.
20. Mashkilleyson N, Mashkilleyson AL. Mucous membrane manifestations of pemphigus vulgaris: a 25-year survey of 185 patients treated with corticosteroids or with combination of corticosteroids with methotrexate or heparin. Acta Derm Venereol 1988;68:413-21.
21. Smith TJ, Bystryn JC. Methotrexate as an adjuvant treatment for pemphigus vulgaris. Arch Dermatol 1999;135:1275-6.
22. Guzzo C. Folic acid supplementation with methotrexate therapy: what benefit if any?. J Am Acad Dermatol 1994;31:689.
23. Ashton H, Beveridge GW, Sevenson CJ. Therapeutics: XI. Immunosuppressive drugs. Br J Dermatol 1970;83:326-30.
24. Burton JL, Greaves HW, Marks J, Danbar RP. Azathioprine in pemphigus vulgaris. Br Med J 1970;3:84-6.
25. Burton JL, Greaves MW. Azathioprine for pemphigus and pemphigoid: a 4 year follow-up. Br J Dermatol 1974;91:103-9.
26. Lennard L. Pharmacogenetics of acute azathioprine toxicity: relationship to TMPT genetic polymorphism. Clin Pharmacol Ther 1989;46:149-54.
27. Roenigk HH, Deodhar S, Pemphigus treatment with azathioprine clinical and immunologic correlation. Arch Dermatol 1973;107:353-7.
28. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff R. Azathioprine in the treatment of pemphigus vulgaris: a long term follow-up. J Am Acad Dermatol 1987;16:527-33.
29. Moore R, Griffin P, Darby C, Jurewicz A, Lord R. Mycophenolate mofetil for prevention of acute rejection. Lancet 1995;346:253.
30. Lynch WS, Roenigk HH. Mycophenolic acid for psoriasis. Arch Dermatol 1977;113:1203-8.
31. Morris RE, Wang J, Blum JR, Flavin T, Murphy MP, Almquist SJ et al. Immunosuppressive effects of the morpholinoefhyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc 1991;23(2 Suppl 2):19-25.
32. Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997;349:541.
33. Nousari HC, Sragovich A, Kimyai-Asadi A, Orlinsky D, Anhalt GJ. Mycophenolate mofetil in autoimmune and inflammatory skin disorders. J Am Acad Dermatol 1999;40(2 Pt 1):265-8.
34. Chiang H, Sirois DA, Bielory L. Chronic oral mucosal ulceration in a 54-year-old female. Ann Allergy Asthma Immunol 2000;84:391-5.
35. Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997;350:494.
36. Grundmann-Kollmann M, Korting HC, Behrens S, Kaskel P, Leiter U, Krahn G et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 1999;40(6 Pt 1):957-60.
37. Grundmann-Kollmann M, Kaskel P, Leiter U, Krahn G, Behrens S, Peter RU et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999;135:724-5.
38. Bredhch RO, Grundmann-Kollmann M, Behrens S, Kerscher M, Peter RU. Mycophenolate mofetil monotherapy for pemphigus vulgaris. Br J Dermatol 1999;141:934.
39. Ebringer A, MacKay IR. Pemphigus vulgaris treated successfully with cyclophosphamide. Ann Intern Med 1969;71:125-7.
40. Glickman FS, Silvers SH. Pemphigus vulgaris treated with cyclophosphamide. Arch Dermatol 1973;107:467-8.
41. Fellner MJ, Katz JM, McCabe JB. Successful use of cyclophosphamide and prednisone for initial treatment pemphigus vulgaris. Arch Dermatol 1978;114:889-94.
42. Pasricha JS, Sood VD, Minocha Y. Treatment of pemphigus with cyclophosphamide. Br J Dermatol 1975;93:573-6.
43. Ahmed AR, Hombal S. Use of cyclophosphamide in azathioprine failures in pemphigus. J Am Acad Dermatol 1987;17:437-42.
44. Citarella P, Gebbia V, Di Marco P, Tambone Reyes M, Noto G, Aricò M. Cyclophosphamide plus vincristine and prednisone in the treatment of severe pemphigus vulgaris refractory to conventional therapy. J Chemother 1992;4:56-8.
45. Mobini N, Padilla T Jr, Ahmed AR. Long-term remission in selected patients with pemphigus vulgaris treated with cyclosporine. J Am Acad Dermatol 1997,36(2 Pt 1):264-6.
46. Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: preliminary study. J Am Acad Dermatol 1994;30(5 Pt 1):752-7.
47. Vardy DA, Cohen AD. Cyclosporine therapy should be considered in maintenance of remission in patients with pemphigus. Arch Dermatol 2001;137:505-6.
48. Ioannides D, Chrysomallis F, Bystryn JC. Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000;136:868-72.
49. Aeschlimann A, Brackertz D, Kaiser H, Muller W. [Chlorambucil pulse therapy in progressive chronic polyarthritis. Initial results of an open multicenter study]. Z Rheumatol 1987;46:241-4.
50. Snaith ML, Holt JM. Chlorambucil in the treatment of systemic lupus erythematosus. Am Heart J 1974;87:533-5.
51. Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum 1993;36:319-24.
52. Elliot JH, Ballinger WH. Behcet's syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc 1984;82:264-81.
53. Shah N, Green AR, Elgart GW, Kerdel F. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000;42(1 Pt 1):85-8.
54. Penneys NS, Eaglestein WH, Inogin S, Frost P. Gold sodium thiomalate treatment of pemphigus. Arch Dermatol 1973;108:56-60.
55. Penneys NS, Eaglestein WH, Frost P. Management of pemphigus with gold compounds: a long term follow-up report. Arch Dermatol 1976;112:185-7.
56. Poulin Y, Perry HU, Muller SA. Pemphigus vulgaris: results of treatment with gold as a steroid sparing agent in a series of 13 patients. J Am Acad Dermatol 1984;11:851-7.
57. Pandya AG, Dyke G. Treatment of pemphigus with gold. Arch Dermatol 1998;134:1104-7.
58. Hayag MV, Cohen JA, Kerdel FA. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol 2000;43:1065-9.
59. Nousari CH, Brodsky R, Anhalt GJ. Evaluating role of immunoablative high dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003;49:148-50.
60. Pasricha JS, Thanzama J, Khan UK. Intermittent high-dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 1988;119:73-7.
61. Cummins DL, Mimouni D, Anhalt GJ, Nousari CH. Oral cyclophosphamide for treatment of pemphigus vulgaris and foliaceus. J Am Acad Dermatol 2003;49:276-80.
62. Hietanen J, Salo OP. Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978. Acta Derm Venereol 1982;62:491-6.
63. Kaur S, Kanwar AJ. Dexamethasone-cyclophosphamide pulse therapy in pemphigus. Int J Dermatol 1990;29:371-4.
64. Pasricha JS, Das SS. Curative effect of dexamethasone-cyclophosphamide pulse therapy for the treatment of pemphigus vulgaris. Int J Dermatol 1992;31:875-7.
65. Pasricha JS, Khaitan BK, Raman RS, Chandra M. Dexamethasone- cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995;34:875-82.
66. Kumrah L, Ramam M, Shah P, Pandey RM, Pasricha JS. Pituitary-adrenal function following dexamethasone-cyclophosphamide pulse therapy for pemphigus. Br J Dermatol 2001;145:944-8.
67. Kanwar AJ, Kaur S, Thami GP. Long-term efficacy of dexamethasone- cyclophosphamide pulse therapy in pemphigus. Dermatology 2002;204:228-31.
68. Pandya AG, Sonmeimer RD. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992;128:1626-30.
69. Ruocco V, Rossi A, Argenziano G, Aatarita C, Alviggi L, Farzati B, Papaleo G. Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. Br J Dermatol 1978;98:237-41.
70. Cotterill JA, Barker DJ, Millard LG. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1978;98:243.
71. Meurer M, Braun-Falco O. Plasma exchange in the treatment of pemphigus vulgaris. Br J Dermatol 1979;100:231-2.
72. Auerbach R, Bystryn JC. Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. Arch Dermatol 1979;115:728-30.
73. Coverton RW, Armstrong RB. Acanthosis nigricans developing in resolving lesions of pemphigus vulgaris. Arch Dermatol 1982;118:115-6.
74. Ruocco V, Astarita C, Pisani M. Plasmapheresis as an alternative or adjunctive therapy in problem cases of pemphigus. Dermatologica 1984;168:219-23.
75. Euler HH, Löffler H, Christophers E. Synchronization of plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris. Arch Dermatol 1987;123:1205-10.
76. Fine JD, Appell ML, Green LK, Sams WM. Pemphigus vulgaris. Combined treatment with intravenous corticosteroid pulse therapy, plasmapheresis, and azathioprine. Arch Dermatol 1988;124:236-9.
77. Blaszczyk M, Chorzelski TP, Jablonska S, Daszynski J, Beutner EH. Indications for future studies on the treatment of pemphigus with plasmapheresis. Arch Dermatol 1989;125:843-4.
78. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990;22:35-40.
79. Soøndergaard K, Carstens J, Zachariae H. The steroid-sparing effect of long-term plasmapheresis in pemphigus: an update. Ther Apher 1997;1:155-8.
80. Thakur BK, Bernardi DM, Murali MR, McClain SA, Clark RA. Invasive cutaneous aspergillosis complicating immunosuppressive therapy for recalcitrant pemphigus vulgaris. J Am Acad Dermatol 1998;38:488-90.
81. Ogata K, Yasuda K, Matsushita M, Kodama H. Successful treatment of adolescent pemphigus vulgaris by immunoadsorption method. J Dermatol 1999;26:236-9.
82. Yano C, Ishiji T, Kamide R, Niimura M. A case of pemphigus vulgaris successfully treated with single filtration plasmapheresis: a correlation of clinical disease activity with serum antibody levels. J Dermatol 2000;27:380-5.
83. Shapiro M, Jimenez S, Werth VP. Pemphigus vulgaris induced by D-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol 2000;42:297-9.
84. Turner MS, Sutton D, Sauder DN. The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2000;43:1058-64.
85. Bystryn JC, Graf MW, Uhr JW. Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. J Exp Med 1970;132:1279-87.
86. Sams WM Jr, Schur PH. Studies of the antibodies in pemphigoid and pemphigus. J Lab Clin Med 1973;82:249-54.
87. Jones JV. Response to apheresis: problems of assessment in immune disease. Clin Nephrol 1986;26 Suppl 1:S70-5.
88. Hida M, Takamiya T, Kitamura M, Iida T, Kitajima N, Hiraga S et al. Clinical reports on plasma exchange in the Kidney Center, Tokai University School of Medicine. Tokai J Exp Clin Med 1987;12:61-6.
89. Stanley JR. Pathophysiology and therapy of pemphigus in the 21st century. J Dermatol 2001;28:645-6.
90. Wenz B, Barland P. Therapeutic intensive plasmapheresis. Semin Hematol 1981;18:147-62.
91. Terman DS, Garcia-Rinaldi R, Dannemann B, Moore D, Crumb C, Tavel A et al. Specific suppression of antibody rebound after extracorporeal immunoadsorption. I. Comparison of single versus combination chemotherapeutic agents. Clin Exp Immunol 1978;34:32-41.
92. Derksen RH, Schuurman HJ, Gmelig Meyling FH, Struyvenberg A, Kater L. Rebound and overshoot after plasma exchange in humans. J Lab Clin Med 1984;104:35-43.
93. Roujeau JC, Andre C, Joneau Fabre M, Lauret P, Flechet ML, Kalis B et al. Plasma exchange in pemphigus. Uncontrolled study of ten patients. Arch Dermatol 1983;119:215-21.
94. Ruocco V. Plasmapheresis and pulse cyclophosphamide therapy in pemphigus vulgaris: a novelty or a reappraisal? Arch Dermatol 1988;124:1716-8.
95. Bystryn JC. Plasmapheresis therapy of pemphigus. Arch Dermatol 1988;124:1702-4.
96. Guillaume JC, Roujeau JC, Morel P, Doutre MS, Guillot B, Lambert D et al. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988;124:1659-63.
97. Roujeau JC. Plasmapheresis therapy of pemphigus and bullous pemphigoid. Semin Dermatol 1988;7:195-200.
98. Korman N. Pemphigus. J Am Acad Dermatol 1988;18:1219-38.
99. Heald P, Knobler R, LaRoche L. Photoinactivated lymphocyte therapy of cutaneous T-cell lymphoma. Dermatol Clin 1994;12:443-9.
100. Edelson RL. Photopheresis: a new therapeutic concept. Yale J Biol Med 1989;62:565-77.
101. Rook AH, Cohen JH, Lessin SR, Vowels BR. Therapeutic applications of photopheresis. Dermatol Clin 1993;11:339-47.
102. Gross M, Boh EE, Millikan LE. Extracorporeal photopheresis. In J Dermatol 1994;33:407-11.
103. Edelson RL. Photopheresis: a clinically relevant immunobiologic response modifier. Ann N Y Acad Sci 1991;636:154-64.
104. Azana JM, de Misa RF, Harto A, Ledo A, Espana A. Severe pemphigus foliaceus treated with extracorporeal photochemotherapy. Arch Dermatol 1997;133:287-9.
105. Perotti C, Torretta L, Viarengo G, Roveda L, Bernuzzi S, Carbone S et al. Feasibility and safety of a new technique of extracorporeal photochemotherapy: experience of 240 procedures. Haematologica 1999;84:237-41.
106. Efferth T, Fabry U, Osieka R. Induction of apoptosis, depletion of glutathione, and DNA damage by extracorporeal photochemotherapy and psoralen with exposure to UV light in vitro. Anticancer Res 2001;21:2777-83.
107. Rook AH, Jegasothy BV, Heald P, Nahass GT, Ditre C, Witmer WK et al. Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. Ann Intern Med 1990;112:303-5.
108. Rook AH, Heald PW, Nahass GT, Macey W, Witmer WK, Lazarus GS et al. Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris: preliminary report. Yale J Biol Med 1989;62:647-52.
109. Rook AH. Photopheresis in the treatment of autoimmune disease: experience with pemphigus vulgaris and systemic sclerosis. Ann N Y Acad Sci 1991;636:209-16.
110. Liang G, Nahass G, Kerdel FA. Pemphigus vulgaris treated with photopheresis. J Am Acad Dermatol 1992;26:779-80.
111. Gollnick HP, Owsianowski M, Taube KM, Orfanos CE. Unresponsive severe generalized pemphigus vulgaris successfully controlled by extracorporeal photopheresis. J Am Acad Dermatol 1993;28:122-4.
112. Wollina U, Lange D, Looks A. Short-time extracorporeal photochemotherapy in the treatment of drug-resistant autoimmune bullous diseases. Dermatology 1999;198:140-4.
113. Wolfe JT, Lessin SR, Singh AH, Rook AH. Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. Artif Organs 1994;18:888-97.
114. Schmidt E, Klinker E, Opitz A, Herzog S, Sitaru C, Goebeler M et al. Protein A immunoadsorption: a novel way and effective adjuvant treatment in severe pemphigus. Br J Dermatol 2003;148:1222-9.
115. Shimanovich I, Herzog S, Schmidt E, Opitz A, Klinker E, Brocker EB et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006;31:768-74.
116. Luftl M, Stauber A, Mainka A, Klingel R, Schuler G, Hertl M. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003;149:598-605.
117. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
118. Abe T, Kawasugi K. Use of intravenous immunoglobulin in various medical conditions: a Japanese experience. Cancer 1991;68:1454-9.
119. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999;140:865-74.
120. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989;20:684-5.
121. Humbert P, Derancourt C, Aubin F, Agache P. Effects of intravenous gamma-globulin in pemphigus. J Am Acad Dermatol 1990;22:326.
122. Messer G, Sizmann N, Feucht H, Meurer M. High-dose intravenous immunoglobulins for immediate control of severe pemphigus vulgaris. Br J Dermatol 1995;133:1014-6.
123. Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995;133:289-93.
124. Bewley AP, Keefe M. Successful treatment of pemphigus vulgaris by pulsed intravenous immunoglobulin therapy. Br J Dermatol 1996;135:128-9.
125. Wever S, Zillikens D, Bröcker EB. Successful treatment of refractory mucosal lesions of pemphigus vulgaris using intravenous gammaglobulin as adjuvant therapy. Br J Dermatol 1996;135:862-3.
126. Colonna L, Cianchini G, Frezzolini A, De Pità O, Di Leila G, Puddu P. Intravenous immunoglobulins for pemphigus vulgaris: adjuvant or first choice therapy? Br J Dermatol 1998;138:1102-3.
127. Jolles S, Hughes J, Rustin M. Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. J Am Acad Dermatol 1999;40:499-500.
128. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulin in management of pemphigus vulgaris. J Am Acad Dermatol 2000;43:1049-57.
129. Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001;45:679-90.
130. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002;138:1158-62.
131. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol2003;139:1051-9.
132. Wetter DA, Davis MD, Yiannias JA, Gibson LE, Dahl MV, el-Azhary RA et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005;80:41-7.
133. Segura S, Iranzo P, Martinez-de Pablo I, Mascaro JM Jr, Alsina M, Herrero J et al. High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases. J Am Acad Dermatol 2007;56:960-7.
134. El Tal AK, Posner MR, Spigelman Z, Ahmed AR. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol 2006;55:449-59.
135. Dupuy A, Viguier M, Bedane C, Cordoliani F, Blaise S, Aucouturier F et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004;140:91-6.
136. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002;47:785-8.
137. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004;51:817-9.
138. Espana A, Fernandez-Galar M, Lloret P, Sanchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004;50:974-6.
139. Esposito M, Capriotti E, Guinta A, Bianchi L, Chimenti S. Long lasting remission of pemphigus vulgaris treated with Rituximab. Acta Derm Venerol 2006;86:87-9.
140. Cecchi R, Gasperini U. Severe pemphigus vulgaris treated with rituximab (Mabthera). J Dermatol 2005;32:862-4.
141. Neidermeier A, Worl P, Barth S, Schuler G, Hertl M. Delayed response of oral pemphigus to Rituximab treatment. Eur J Dermatol 2006;16:266-70.
142. Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CE20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol 2006;31:143.
143. Kong HM, Prose NS, Ware RE, Hall RP. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD monoclonal antibody (rituximab). Pediatr Dermatol 2005;22:461-4.
144. Marzano AV, Fanoni D, Venegoni L, Berti E, Caputo R. Treatment of refractory pemphigus with anti-CD 20 monoclonal antibody (rituximab). Dermatology 2007;214:310-8.
145. Antonucci A, Negosanti M, Tabanelli M, Varotti C. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): five cases. J Dermatolog Treat 2007;18:178-83.
146. Goh HS, McCormack C, Dinh HV, Welsh B, Foley P, Prince HM. Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-labeled pilot study in five patients. Br J Dermatol 2007;156:990-6.
147. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9.
148. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005;153:222-3.
149. Jacobi A, Shuler G, Hertl M. Rapid control of therapy refractory pemphigus vulgaris by treatment with the tumor necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005;153:448-9.
150. Lin MH, Hsu CR, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with Etanercept and Carbon dioxide laser. Arch Dermatol 2005;141:680-2.
151. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with tumor necrosis factor alpha antagonist etanercept. Cutis 2004;74:245-7.
152. Olszewska M, Kolacinska-Strasz Z, Sulej J, Labecka H, Cwikla J, Natorska U et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol 2007;8:85-92.
153. Shahidi-Daoras M, Karami A, Toopayt P, Safiyan A. Pulse versus oral methylprednisolone therapy in pemphigus vulgaris. Arch Iran Med 2007;10:1-6.
154. Mentink LF, Mackenzie MW, Toth GG, Laseur M, Lambert FP, Veeger NJ et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006;142:570-6. Erratum in: Arch Dermatol 2006;142:1014.
155. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; [Epub ahead of print].
156. Rose E, Wever S, Zilliken D, Linse R, Haustein UF, Brocker EB. Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005;3:200-6.
157. Beissert S, Werfel T, Frieling U, Bohm M, Sticherling M, Stadler R et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006;142:1447-54.
158. Seiden Baum M, David M, Sandbank M. The course and prognosis of pemphigus. A review of 115 patients. Int J Dermatol 1988;27:580-4.
159. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000;42:422-7.